Product Description
An oral, small molecule inhibitor of TIGIT and PDL1, developed from Aurigene’s small molecule IO platform. In contrast to antibodies, AUR-106 offers the advantages of ease of combination dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs. (Sourced from: https://www.aurigene.com/pipeline/#proprietary-pipeline)
Mechanisms of Action: TIGIT Inhibitor,PD-L1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aurigene Discovery Technologies
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for AUR-106](https://pryzm-maps.s3.us-west-2.amazonaws.com/260current_maps.png)
Countries in Clinic: India
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Kidney Cancer|Non-Small-Cell Lung Cancer|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JIVAN | P1 |
Recruiting |
Transitional Cell Carcinoma|Esophageal Cancer|Kidney Cancer|Colorectal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer |
2025-05-01 |
44% |